KYMR — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-10-29

• We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current product candidates or any future product candidate…

• Comparison of three months ended September 30, 2026 and 2025

• The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025:

• There was no impairment on long-lived assets for the three months ended September 30, 2026, compared to $3.9 million for three months ended September 30, 2025. The decrease of $3.9 million was the result of an incremental impairment charge taken on the 2019 Lease due to the continued worsening of ma…

• Other income, net was $15.2 million for the three months ended September 30, 2026, compared to $10.3 million for the three months ended September 30, 2025. The $4.9 million increase was primarily due to an increase in the cash, cash equivalents, and marketable securities balances resulting in higher…

Text removed vs the prior filing · source: 10-Q · 2026-08-05

• placement, our subsequent follow-on offerings and private placement offering, our prior sales agreement with Cowen and through our corporate collaborations.

• We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current product candidates or any future product candidate…

• The following table summarizes our results of operations for the three months ended June 30, 2026 and 2025:

• Other income, net was $14.4 million for the three months ended June 30, 2026, compared to $7.9 million for the three months ended June 30, 2025. The $6.5 million increase was primarily due to an increase in the cash, cash equivalents, and marketable securities balances resulting in higher interest i…

• The following table summarizes our results of operations for the six months ended June 30, 2026 and 2025:

Text added vs the prior filing · source: 10-Q · 2026-10-29

• the evolving geopolitical landscape that may limit or restrict access to foreign clinical trial sites and/or foreign clinical trial data and documentation;

• fines, FDA Form 483s, warning letters or holds on clinical trials;

• changes to U.S. trade policies, sanctions, legislation, treaties, and tariffs;

• The FCPA and similar laws and regulations prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corru…

• requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our res…

Text removed vs the prior filing · source: 10-Q · 2026-08-05

• enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, then our ability to access our cash, cash equivalents and marketable securities may be threatened, which could have a material adverse effect on our business a…

• uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates.

• and clinical development programs could be restricted due to developments between the United States and China, including as a result of the escalation of tariffs or other trade restrictions.

• BIOSECURE-related restrictions, and any future legislative, regulatory, or administrative actions expanding or modifying these restrictions, could negatively impact U.S. companies and institutions that accept U.S. funding for projects that utilize biotechnology equipment or services produced or prov…

• In addition, federal regulators are imposing new and heightened protections for health and other sensitive information that could impact our business. For example, the FTC has imposed stringent requirements on the collection and disclosure of sensitive categories of personal information, including h…